Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03919994 · ClinicalTrials.gov registry record
Observational Study of Long Acting Injectable Medications (LAIs) in Schizophrenia (OASIS)
A clinical trial, sponsored by Alkermes.
- Completed
- Registry status
- 338
- Enrollment target
NCT03919994: Completed study, sponsored by Alkermes.
NCT03919994 is a clinical trial that has completed, run by Alkermes. The registered enrollment target is 338 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03919994 has completed, sponsored by Alkermes.
- COMPLETED
- Registry status
- 338 participants
- Enrollment target
Study Summary
The objectives of this study are to describe characteristics, treatment patterns, and outcomes of patients with schizophrenia newly initiated on 1 of 4 FDA-approved atypical Long Acting Injectable (LAI) antipsychotics (ABILIFY MAINTENA®, ARISTADA®, INVEGA SUSTENNA® or RISPERDAL CONSTA®)
Primary Outcome
Including time (years) since diagnosis as assessed from clinical history
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 338 participants |
| Start Date | 2019-03-28 |
| Est. Completion | 2023-01-04 |
What the finished NCT03919994 record still lists
NCT03919994 is an observational study that tracks outcomes without assigning an intervention. The registered 338 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT03919994 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03919994 about?
NCT03919994 is a clinical study titled "Observational Study of Long Acting Injectable Medications (LAIs) in Schizophrenia (OASIS)". The objectives of this study are to describe characteristics, treatment patterns, and outcomes of patients with schizophrenia newly initiated on 1 of 4 FDA-approved atypical Long Acting Injectable (LAI) antipsychotics (ABILIFY MAINTENA®, ARISTADA®, INVEGA SUSTENNA® or RISPERDAL CONSTA®)
What is the current status of trial NCT03919994?
This trial is currently completed. The enrollment target is 338 participants. The study started on 2019-03-28. Estimated completion is 2023-01-04.
Who is sponsoring clinical trial NCT03919994?
This trial is sponsored by Alkermes, which has 66 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03253263 · 338 participants · Phase 2
A Clinical Efficacy and Safety Study of OHB-607 in Preventing Bronchopulmonary Dysplasia in Extremely Premature Infants
- NCT05658731 · 338 participants · NA
Cognitive Outcomes After Brain Substructure-informed Radiation Planning in Pediatric Patients
- NCT06022939 · 338 participants · Phase 3
Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis
- NCT04176172 · 340 participants · Phase 3
Optimizing Tobacco Use Treatment for PLWHA
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI